跳至主要内容
临床试验/JPRN-UMIN000007787
JPRN-UMIN000007787已完成3 期

Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancer - EXPERT

Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo0 个研究点目标入组 500 人开始时间: 2012年4月19日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Extrahepatic metastases or history of extrahepatic metastases (2) Metachronous 1 liver metastasis (3) More than 9 liver metastases (4) Prior local therapy for liver metastases (5) Severe comorbidity (6) Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval (7) Severe infectious disease (8) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding . Women with a positive pregnancy test (9) Psychological disorder (10) Considered not appropriate for surgery

研究者

发起方
Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo

相似试验

尚未招募
3 期
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to imatinib mesylateGastro-intestinal stromal tumour (GIST)Cancer - Other cancer types
ACTRN12609000681257European Organisation for Research and Treatment of Cancer (EORTC)350
尚未招募
3 期
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.bowel wall cancer1001799010017998GIST
NL-OMON32805European Organisation for Research in Treatment of Cancer (EORTC)60
进行中(未招募)
不适用
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
EUCTR2007-002257-23-GBEuropean Organization for Research and Treatment of Cancer350
进行中(未招募)
1 期
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.Metastatic gastro-intestinal stromal tumorMedDRA version: 9.1Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumor
EUCTR2007-002257-23-FREuropean Organization for Research and Treatment of Cancer350
进行中(未招募)
不适用
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
EUCTR2007-002257-23-NLEuropean Organization for Research and Treatment of Cancer350